Mechanistic role of CXCL5 in cardiovascular disease, diabetes mellitus, and kidney disease

被引:8
|
作者
Chen, Ching [1 ]
Chang, Ting-Ting [1 ,2 ]
Chen, Jaw-Wen [1 ,3 ,4 ,5 ,6 ,7 ,8 ]
机构
[1] Natl Yang Ming Chiao Tung Univ, Dept & Inst Pharmacol, Sch Med, Taipei, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Biomed Ind PhD Program, Taipei, Taiwan
[3] Taipei Med Univ Hosp, Div Cardiol, Dept Med, Taipei, Taiwan
[4] Taipei Med Univ Hosp, Dept Res, Taipei, Taiwan
[5] Taipei Med Univ Hosp, Cardiovasc Res Ctr, Taipei, Taiwan
[6] Taipei Med Univ, Taipei, Taiwan
[7] Natl Yang Ming Chiao Tung Univ, Cardiovasc Res Ctr, Taipei, Taiwan
[8] Taipei Med Univ Hosp, Dept Res, Taipei, Taiwan
关键词
Chemokine; Cardiovascular disease; Diabetes mellitus; Kidney disease; CXCL5; CHEMOKINE RECEPTORS; PEPTIDE ENA-78; NEUTROPHIL RECRUITMENT; LIGAND; 5; CELLS; EXPRESSION; CYTOKINES; OBESITY; INFLAMMATION; HOMEOSTASIS;
D O I
10.1016/j.lfs.2023.122018
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Chemokines, by modulating inflammation process, could contribute to the development of cardiovascular dis-ease, diabetes mellitus (DM), and kidney disease. Chemokine CXC motif ligand 5 (CXCL5) is one of the inducible chemokines that may be involved in various inflammatory diseases. Given the bidirectional promiscuity char-acteristics of the chemokine system, the mechanistic roles of CXCL5 should be further explored in each specific disease. In this article, we sought to review the recent evidence on the differential effects of CXCL5 and their potential mechanisms in cardiovascular disease, DM, and renal disease individually. Future study is still required to verify if CXCL5 could be a novel therapeutic target in these diseases.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Circulating CXCL16 in Diabetic Kidney Disease
    Elewa, Usama
    Sanchez-Nino, Maria D.
    Mahillo-Fernandez, Ignacio
    Martin-Cleary, Catalina
    Ana, Belen Sanza
    Perez-Gomez, Maria Vanessa
    Fernandez-Fernandez, Beatriz
    Ortiz, Alberto
    KIDNEY & BLOOD PRESSURE RESEARCH, 2016, 41 (05) : 663 - 671
  • [32] Cardiovascular disease risk in youth with diabetes mellitus
    Wadwa, R. Paul
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2006, 7 (03) : 197 - 204
  • [33] CXCL5 plasma levels decrease in patients with chronic liver disease
    Tacke, Frank
    Zimmermann, Henning W.
    Trautwein, Christian
    Schnabl, Bernd
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 (03) : 523 - 529
  • [34] Diabetes and Cardiovascular Disease Following Kidney Transplantation
    Boerner, Brian P.
    Shivaswamy, Vijay
    Desouza, Cyrus V.
    Larsen, Jennifer L.
    CURRENT DIABETES REVIEWS, 2011, 7 (04) : 221 - 234
  • [35] MicroRNAs and Cardiovascular Disease in Diabetes Mellitus
    Ding, Yue
    Sun, Xue
    Shan, Peng-Fei
    BIOMED RESEARCH INTERNATIONAL, 2017, 2017
  • [36] Homocysteine and cardiovascular disease in diabetes mellitus
    Audelin, MC
    Genest, J
    ATHEROSCLEROSIS, 2001, 159 (02) : 497 - 511
  • [37] Diabetes mellitus and kidney disease in the elderly
    Iglesias, Pedro
    Heras, Manuel
    Diez, Juan J.
    NEFROLOGIA, 2014, 34 (03): : 285 - 292
  • [38] Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus
    Athanasakis, G.
    Papazafiropoulou, A.
    ARCHIVES OF HELLENIC MEDICINE, 2022, 39 (01): : 17 - 23
  • [39] Acromegaly accompanied by diabetes mellitus and polycystic kidney disease
    Otani, Daisuke
    Murakami, Takaaki
    Matsubara, Takeshi
    Hojo, Masato
    Nakae, Takuro
    Moriyoshi, Koki
    Yasoda, Akihiro
    Usui, Ryota
    Tatsuoka, Hisato
    Ogura, Masahito
    Inagaki, Nobuya
    Yamamoto, Taizou
    ENDOCRINE JOURNAL, 2021, 68 (01) : 103 - 110
  • [40] Diabetes Mellitus and Cardiovascular Disease Emerging Therapeutic Approaches
    Schmidt, Ann Marie
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (04) : 558 - 568